Samsung Bioepis wins FDA approval for rheumatoid arthritis drug that competes with Johnson & Johnson

South Korea’s Samsung Bioepis has won a U.S. FDA nod for a biosimilar of Johnson & Johnson’s Remicade, marking a first for the company in the U.S. and setting up a path to competition with the world’s largest drug company and a similar product...